Inspira Technologies partners with Qarakal Quantum for quantum computing cryogenic interconnects

Inspira Technologies (IINN) announced on April 30, 2026, a joint development agreement with Qarakal Quantum to co-develop cryogenic interconnects for quantum computing infrastructure. The partnership will leverage Inspira's QTREX additive manufacturing technology to address high-performance signal connectivity challenges in cryogenic environments. The companies will conduct 3D-printed structure testing and performance evaluation aimed at improving scalability of quantum computing systems under extreme low-temperature conditions. Inspira projects 2026 revenue of $48 million, a 16,509% year-over-year increase, though EPS is expected to turn negative at -$0.11 due to upfront R&D investment.

This partnership represents a novel application of metal AM beyond its traditional strongholds in aerospace and medical devices, targeting the specialized thermal and electrical performance requirements of quantum computing hardware. The QTREX process is being positioned to solve a specific bottleneck: cable density and thermal efficiency in cryostats, where conventional manufacturing struggles to produce the complex, miniaturized geometries needed for scalable qubit control. While the revenue projection is dramatic, it reflects a small base effect and likely includes non-recurring engineering milestones rather than sustained production. The deal fits the pattern of AM companies seeking adjacent high-value technical niches where subtractive methods fall short, but quantum infrastructure remains a pre-commercial market with uncertain volume timelines.

For Inspira, the practical challenge is translating prototype interconnects into repeatable, qualified production at the tolerances and material purity levels quantum systems demand. The company must demonstrate that QTREZ can deliver consistent cryogenic performance across multiple test cycles before this becomes a revenue-generating product line rather than a funded development project. The medical device business remains the nearer-term anchor.